1 / 34

Alemtuzumab

Alemtuzumab. Lynne Nakashima, BSc(Pharm), Pharm.D Nov. 29, 2003. Outline . What is Alemtuzumab? Mechanism of action Indication for Use BCCA Protocol Summary Dosage and Administration Sample Pre-printed Order Adverse Effects Health Canada’s Special Access Program

kiri
Download Presentation

Alemtuzumab

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Alemtuzumab Lynne Nakashima, BSc(Pharm), Pharm.D Nov. 29, 2003

  2. Outline • What is Alemtuzumab? • Mechanism of action • Indication for Use • BCCA Protocol Summary • Dosage and Administration • Sample Pre-printed Order • Adverse Effects • Health Canada’s Special Access Program • Summary of Data from the BCCA

  3. What is Alemtuzumab? • Unconjugated, nonmodulating, humanised IgG1 kappa monoclonal antibody which targets the CD52 antigen • Recombinant DNA derived

  4. Mechanism of ActionCD52 • 21-28 kD cell surface glycoprotein • Expressed on more than 95% of malignant and normal T and B cells (lymphocytes, monocytes, macrophages, eosinophils) • Function is unknown

  5. Mechanism of Action (2) • Alemtuzumab binds to CD52 bearing cells • Causes cell death through host-effector mechanisms (complement-mediated lysis, antibody dependent cellular cytotoxicity)

  6. Indication for Use B-Chronic Lymphocytic Leukemia (CLL) • Most common adult leukemia in western hemisphere (20-30%) • Median age at diagnosis is 64 years • 95% of patients express CD52 • Treatment options: chlorambucil, fludarabine

  7. Indication for Use (2) T-Prolymphocytic Leukemia (T-PLL) • Rare aggressive post thymic malignancy • Treatment options: cladribine, chlorambucil, fludarabine

  8. Clinical Efficacy • To date, all studies in B-CLL and T-PLL have been non-comparative, phase I/II trials

  9. Clinical Efficacy (2) Blood 2002;99(10):3554-61 • Phase II, 93 patients relapsed/refractory B-CLL • OR = 33% (CR 2%, PR 31%) • Median duration of response = 8.7 mo • At median follow-up of 29 mo, median survival = 16 mo (historical control 8 mo)

  10. Clinical Efficacy (3) T-PLL: • 4 non-comparative trials (n=12-76) • OR rates = 24-76% JCO 2002;20(1):205-13 • 76 compassionate treated patients • OR = 50% (CR 37.5%, PR 12.5%) • Median duration of CR = 8.7 mo

  11. BCCA Protocol SummaryULYALEM BCCA Protocol Summary for theTreatment of Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) and T-Prolymphocytic Leukemia (T-PLL) with Alemtuzumab www.bccancer.bc.ca

  12. Eligibility Criteria Patients with B-CLL or T-PLL and • 18 years or older • Have not responded to or had early documented relapse after Fludarabine • Have received at least one alkylating agent-containing regimen • Life expectancy of at least 12 weeks • Rai Stage II, III or IV with symptomatic splenomegaly, lymphadenopathy, or cytopenias related to marrow infiltration or sequestration. • WHO performance status 0-2

  13. Exclusion Criteria • Hypersensitivity reactions to other monoclonal antibody therapies • HIV seropositivity • Pregnant or lactating • New York Heart Association grade III or IV congestive heart failure • Active systemic infection • Bulky (>5 cm) adenopathy at any site • Pre-existing autoimmune cytopenias

  14. Dosage • Dosing three times each week, usually MWF, for maximum of 12 weeks • All doses flat dose in mg, not mg/m2 Week 1: 3 mg 10 mg 30 mg Week 2+: 30 mg 30 mg 30 mg

  15. Dosage (2) • Escalate to 10 mg, then 30 mg only if toxicities grade I or II, and improving. • If grade III or IV reactions occur, lower dose to maximum tolerated dose (3 or 10 mg) until well tolerated for one week, then resume escalation to maximum of 30 mg/dose. • Maximum total weekly dose is 90 mg. • If treatment is interrupted for more than 7 days for any reason, re-initiate treatment at 3 mg, and escalate as above

  16. Dosage (3) Peak Plasma Concentration: 26.4 ug/mL Elimination Half-Life: 12 days

  17. Administration • SC (thigh)(Note: divide 30 mg dose into two injection sites) OR • IV in 100 mL NS over 2 hours • NOTE: Due to ampoule format, draw up dose with a 5 micron filter needle. Discard all unused portions of the ampoule

  18. Sample Pre-Printed Order • Have Available in Treatment Room: • Diphenhydramine 50 mg for IV injection (if required) • Epinephrine 1:1000 1 mL for IV injection (if required, dilute in 10 mL) • Methylprednisolone 125 mg for IV injection (if required) • Salbutamol Nebules plus nebulizer (if required, for inhalation use)

  19. Sample Pre-Printed Order (2) • PREMEDICATION: • Diphenhydramine 50 mg PO prior to Alemtuzumab • Acetaminophen 650 mg PO prior to Alemtuzumab • Prednisone 10 mg PO 15-30 minutes prior to Alemtuzumab for the first two weeks.

  20. Sample Pre-Printed Order (3) IV Alemtuzumab • Alemtuzumab 3 mg OR 10 mg OR 30 mg (circle desired dose) IV in 100 mL NS over 2 hours on day 1, 3, 5 SC Alemtuzumab • Alemtuzumab 3 mg OR 10 mg OR 30 mg (circle desired dose) SC three times weekly (M, W, F)

  21. Adverse EffectsInfusion-Related Events • Rigor, fever, nausea, vomiting, skin rash, dyspnea, hypotension • “flu-like” syndrome • Usually occur during first alemtuzumab infusion • Decrease in intensity and/or frequency during subsequent infusions

  22. Adverse EffectsInfusion-Related Events (2) Premedication • Diphenhydramine 50 mg PO prior to Alemtuzumab • Acetaminophen 650 mg PO prior to Alemtuzumab • Prednisone 10 mg PO 15-30 minutes prior to Alemtuzumab for the first two weeks

  23. Adverse EffectsInfusion-Related Events (3) • Flu-like symptoms may be reduced in severity in patients receiving SC injections • SC injection results in transient injection-site skin reactions during week 1-2; may result in slower dose escalation

  24. Adverse EffectsInfectious Complications • Note: in most phase I/II studies, patients had failed fludarabine • Alemtuzumab causes lymphopenia • Immunosuppression can last several months • Increased risk of infections

  25. Adverse EffectsInfectious Complications (2) • Prophylactic Antibiotics (start at week 1 and continue until 2 months after completion of treatment)Cotrimoxazole 1 DS tab PO 3 times each weekValacyclovir 500 mg PO BIDORAcyclovir 400 mg PO BID

  26. Adverse EffectsInfectious Complications (3) • 55% experience one or more infections • 25% have severe or life-threatening infections • 15% diagnosed with septicemia • 11% diagnosed with opportunistic infections • Retrospective analysis of 1538 patients, overall incidence CMV = 3.6%

  27. Adverse EffectsHematological • Grade III/IV neutropenia = 70% • Grade III/IV thrombocytopenia = 52% • Grade III/IV anemia = 47% • Median duration: 26 days • However, growth factors generally not used in the clinical trials to date

  28. Adverse EffectsHematologic (2) • CBC, diff weekly • Hold dose if ANC < 0.25 x 109/L or platelets < 25 x 109/L • Resume when ANC > 0.5 x 109/L and platelets > 50 x 109/L • If therapy interrupted for more than 7 days, re-institute with gradual dose escalation

  29. Adverse EffectsOther • Immunizations with live vaccines are not permitted, due to immunosuppression • No formal drug interaction studies have been completed

  30. Special Access Program • Not commercially available • Manufacturer: Berlex Canada • Approval from Health Canada SAP program required • Supplied in 30 mg/3 mL ampoules • $650 per ampoule • 12 week course = $23,400

  31. BCCA Data • Undesignated request required • Between July 2002 and Oct. 2003, a total of 21 patients have received approval for 23 courses • 20 CLL, 1 T-PLL • Average time between approvals for repeat treatments = 9.5 mo

  32. BCCA Data (2) Hospitals Requesting Approval: - BCCA - LGH - Royal Columbian - Kamloops - St. Paul’s

  33. Conclusions • Alemtuzumab is a novel medication for the treatment of B-CLL and T-PLL • Future research focusing on combination therapy with chemotherapy

More Related